![2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fcas-image%2Fthumb-webp%2F180418-2-propenoic-acid-3-3-phenylamino-sulfonyl-phenyl-2e.webp&w=3840&q=75)
CAS 866323-87-7
:2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-
Description:
2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-, commonly referred to by its CAS number 866323-87-7, is an organic compound characterized by its propenoic acid backbone, which features a double bond between the first and second carbon atoms. This compound contains a sulfonamide functional group, indicated by the presence of a phenylamino moiety attached to a sulfonyl group, contributing to its potential biological activity. The structure suggests that it may exhibit properties typical of both unsaturated carboxylic acids and sulfonamides, which can influence its reactivity and interactions in various chemical environments. The presence of the phenyl groups may enhance its lipophilicity, potentially affecting its solubility and permeability in biological systems. This compound may be of interest in medicinal chemistry and materials science due to its unique structural features, which could lead to applications in drug development or as a building block in polymer synthesis. However, specific biological activities and applications would require further investigation and characterization.
Formula:C15H13NO4S
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
Belinostat acid
CAS:Belinostat acid is an inorganic compound that has been clinically studied for its potential use in cancer treatment. Belinostat acid is a histone deacetylase inhibitor, which means it prevents the removal of acetyl groups from histones, resulting in gene activation and increased transcription. In vitro studies have shown that belinostat acid can be used to treat cancers by inducing homologous recombination repair and inhibiting cell proliferation. Clinical trials are currently underway to examine the safety and efficacy of this drug as a treatment for solid tumors. The terminal half-life of belinostat acid is about 1 hour, with metabolites being excreted primarily through urine.Formula:C15H13NO4SPurity:Min. 95%Molecular weight:303.3 g/mol
